Cosmetic cross-reference Noindex: medium evidence

Piceatannol

CAS 10083-24-6

Piceatannol (CAS 10083-24-6) is a pharmaceutical compound with 9 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
9
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Piceatannol
CAS Number
10083-24-6
UNII
6KS3LS0D4F
InChIKey
CDRPUGZCRXZLFL-OWOJBTEDSA-N
ChEMBL ID
CHEMBL69863
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
natural product
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE EMBL-EBI ChEMBL 9 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- Potency 18111.89419354839 nM 109 -
- GI50 16004.900689655173 nM 58 -
- IC50 24063.954901960784 nM 51 -
- EC50 46000 nM 10 -
- Ki 6713.75 nM 8 -
- AC50 10290.75 nM 4 -
- IC50 12.25 ug.mL-1 4 -
- Kd 4945 nM 4 -
- MIC 337.5 ug.mL-1 4 -
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Piceatannol used for in pharmaceutical contexts?

Piceatannol (CAS 10083-24-6) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Piceatannol?

No adverse-event association or SIDER side-effect rows are rendered for Piceatannol in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Piceatannol also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Piceatannol with EU status "permitted".

What clinical phase is Piceatannol in?

No phase 1-4 clinical development badge is rendered for Piceatannol because the matched compound identifier rows do not contain a max-phase value.